Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuVen has won $1.68m Phase II small business innovation research (SBIR) grant from the National Institute for Allergy and Infectious Disease for methicillin-sensitive and methicillin-resistant Staphylococcal aureus (MRSA) therapeutics.
Subscribe to our email newsletter
The grant will continue to support the research previously supported by a Phase I SBIR grant, the company said.
With the grant, ImmuVen will continue development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and MRSA.
The company aims to bring IMV0123 through a pre-Investigational New Drug (IND) meeting with the FDA and complete major milestones in the preclinical development of the therapeutic.
ImmuVen is a biotechnology company with technology to discover and develop new biotherapeutics to treat infectious disease, cancer and autoimmune disorders.